Treating Inflammation through Resolution Therapy

SynAct Pharma – a clinical stage biotechnology company.

Immune suppression has long been the default in treating inflammation, delivering symptom relief but often at the cost of safety, durability and true disease modification.

We are challenging this paradigm with a next wave approach built on pro resolution biology, designed to switch off inflammation by restoring immune balance rather than shutting it down.

By reprogramming macrophages towards a pro resolving state we aim to move treatment beyond symptom control towards meaningful disease modification.

At the centre of this strategy is its lead asset, resomelagon (AP1189), a melanocortin receptor agonist designed to drive this pro resolving response.

Watch the video to the left for key takeaways from SynAct’s Capital Markets Day (March 2026).